French imaging software developer Median Technologies is highlighting results from the RELIVE clinical trial regarding its AI-based CADe/CADx software as a medical device for lung cancer screening, eyonis LCS.
The software can improve clinicians' diagnostic accuracy in analyzing low-dose CT lung cancer screening scans, the company said. RELIVE data showed that eyonis LCS achieved statistically significant diagnostic improvement over radiologist reading alone (p = 0.027).
The company plans to file for U.S. Food and Drug Administration (FDA) 510(k) clearance and European Union CE marking in the second quarter of this year, it said.
Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.